Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
It became increasingly likely that seladelpar will ultimately gain regulatory approval.
The stock has given up some of its gains but remains up more than 130% year to date.
CBAY earnings call for the period ending June 30, 2022.
CBAY earnings call for the period ending March 31, 2022.
CBAY earnings call for the period ending December 31, 2021.
CBAY earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.